Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
Digital Agentic AI buoys all stakeholders in oncology, with Eron Kel... At LSX 2025, Eron Kelly, CEO of Concert AI, discussed the work his Boston-based start-up is doing in oncology.
Oncology News and advice from an investor-CEO, with Milenko Cicmil pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.
Oncology Following science to fruition, putting patients first: An AS... At ASCO25, AstraZeneca presented late-breaking data from the DESTINY-Breast09 Phase III trial. Alison Dziarmaga discussed the data with pharmaphorum.
News Pharvaris plans filings for HAE drug after pivotal trial win Pharvaris has reported positive data from a phase 3 trial of its drug for preventing HAE attacks, setting up marketing applications next year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
